Highlights • Maximising outcomes with currently available targeted therapies requires a more contextualised stratified medicine • This requires consideration of the genomic, transcriptomic and immunological context of the targeted aberration • The genomic complexity and instability of human cancer requires the development of appropriate pre-clinical models • When targeting amplifications, it essential to demonstrate that any targeted amplified oncogene is an expressed driver on that amplicon...
